For the board-certified physician, anticonvulsants—specifically the Gabapentinoids—are first-line agents for a wide array of conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, and fibromyalgia. However, their mechanism of action is frequently misunderstood, and their unique pharmacokinetics make them a favorite topic for high-yield board questions.

---

1. The Gabapentinoids: Gabapentin and Pregabalin

Despite their names, gabapentin and pregabalin do not act on GABA receptors ($GABA_A$ or $GABA_B$). They were designed as structural analogs of GABA, but their clinical efficacy comes from a completely different pathway.

Mechanism of Action: The alpha 2 delta Subunit

Gabapentinoids bind specifically to the alpha 2 delta auxiliary subunit of presynaptic voltage-gated calcium channels (VGCCs) in the central nervous system.

• The “Gatekeeper” Effect: By binding to this subunit, the drugs reduce the influx of calcium into the presynaptic terminal.
• Neurotransmitter Inhibition: This reduction in calcium influx inhibits the release of excitatory neurotransmitters, most notably Glutamate, Substance P, and Norepinephrine.
• Targeting Hyperexcitability: Crucially, these drugs primarily bind to “active” or “upregulated” channels. This allows them to dampen the pathologically hyper-excited neurons of a sensitized nervous system while leaving normal, low-level neurotransmission relatively unaffected.

Pharmacokinetics: Gabapentin vs. Pregabalin

The boards frequently test the differences in how these two “cousins” are absorbed and metabolized.

• Gabapentin:
  • Absorption: It utilizes a saturable transport system (the L-amino acid transporter) in the small intestine.
  • The “Ceiling” Effect: As the dose increases, the percentage of the drug absorbed actually decreases. This explains why doubling a dose from 300 mg to 600 mg might increase plasma levels significantly, but moving from 1200 mg to 2400 mg yields diminishing returns.
  • Bioavailability: Highly variable and non-linear.
• Pregabalin:
  • Absorption: Also uses the L-amino acid transporter but is absorbed more efficiently.
  • Bioavailability: >90% regardless of the dose.
  • Potency: Roughly 6 times more potent than gabapentin (e.g., 50 mg of pregabalin approx 300 mg of gabapentin).
  • Scheduling: Unlike gabapentin, pregabalin is a Schedule V controlled substance in the US due to a mild potential for euphoria.

---

2. Sodium Channel Blockers: Carbamazepine and Oxcarbazepine

While gabapentinoids target calcium, older anticonvulsants target the “firing” of the nerve itself via sodium channels.

Carbamazepine (Tegretol)

Carbamazepine is the “gold standard” for Trigeminal Neuralgia. If a board question presents a patient with “lightning-bolt” facial pain triggered by chewing or brushing teeth, carbamazepine is almost always the answer.

• Mechanism: It binds to voltage-gated sodium channels in their inactive state, prolonging the refractory period and preventing high-frequency repetitive firing.
• The HLA-B*1502 Warning: This is a critical board “Must-Know.” In patients of Asian descent, there is a strong association between the HLA-B*1502 allele and the development of Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Genetic screening is mandatory before initiation in these populations.
• Auto-induction: Carbamazepine induces its own metabolism (via CYP3A4). This means that after a few weeks of therapy, the plasma levels may drop, requiring a dose adjustment.

Oxcarbazepine (Trileptal)

A derivative of carbamazepine with a better side-effect profile (no auto-induction).

• High-Yield Side Effect: It is notoriously associated with Hyponatremia (low sodium), especially in the elderly. Monitoring electrolytes is essential.

---

3. Other Anticonvulsants in Pain

• Topiramate (Topamax): Used primarily for Migraine prophylaxis. It has multiple mechanisms: sodium channel blockade, enhancement of GABA, and inhibition of glutamate.
  • Board Pearl: Known for the “Dopamax” effect—cognitive slowing and word-finding difficulties. It also carries a risk of nephrolithiasis (kidney stones) and acute angle-closure glaucoma.
• Valproic Acid: Also used for migraine prophylaxis. It increases GABA levels and inhibits sodium channels.
  • Side Effects: Weight gain, hair loss, and hepatotoxicity. It is highly teratogenic (neural tube defects).

---

4. Clinical Integration: Dosing and Renal Safety

• Renal Clearance: All gabapentinoids are excreted 100% unchanged by the kidneys.
  • Mandatory Adjustment: You must calculate the Creatinine Clearance (CrCl) for every patient. If a patient with stage 4 CKD is given a “standard” dose of gabapentin (e.g., 900 mg TID), they will likely present to the ER with profound sedation, ataxia, or even myoclonus.
• Perioperative Use: There is significant evidence for using gabapentinoids as part of a “Multimodal Analgesia” protocol to reduce post-operative opioid consumption.

---

5. Historical and Theoretical Depth: The Transition to Centralized Pain

The use of anticonvulsants in pain medicine validated the theory that chronic pain is a “neurological disorder” rather than just a prolonged “injury signal.” In the late 20th century, researchers noted that the “ectopic discharges” of damaged peripheral nerves looked remarkably similar to the “paroxysmal discharges” seen in epilepsy. This led to the breakthrough that the nervous system can be “stabilized” using similar membrane-stabilizing drugs. Today, we view these medications not just as pain-blockers, but as “volume-control” knobs that reset the gain on a hyper-excitable CNS.

---

6. High-Yield Board “Fast Facts”

• Alpha-2-Delta ($\alpha_2\delta$): The specific binding site for Gabapentin and Pregabalin.
• Renal Failure: The #1 cause of gabapentinoid toxicity; check the GFR!
• Trigeminal Neuralgia: Carbamazepine is the first-line treatment.
• HLA-B*1502: Mandatory screening for Carbamazepine in Asian populations.
• Hyponatremia: The most common electrolyte abnormality with Oxcarbazepine.
• Saturable Transport: The reason for Gabapentin’s non-linear pharmacokinetics.
• L-amino acid transporter: The vehicle for gabapentinoid absorption in the gut.